ABT vs BRX · P/E 25, rev $44.33B vs P/E 24, rev $354.2M
Abbott Laboratories (ABT) versus Brixmor Property (BRX) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Brixmor Property (BRX) is a reit - retail company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported BRX revenue for 2026-06-30 was $354.2M. Net income was $73.5M. Revenue was down 0.2% from 2026-03-31 to 2026-06-30. BRX currently screens at market cap $7.81B and trailing P/E 24.3.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. BRX currently screens at market cap $7.81B and trailing P/E 24.3.
Not investment advice. Open the ABT and BRX stock pages for the full models.
Not investment advice.